Amundi’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Amundi’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-65,989	Closed	-$7.17M	–	2155
2023 Q1	$7.17M	Buy	+65,989	New	+$7.6M	﹤0.01%	923
2022 Q4	–	Sell	-3,460	Closed	-$206K	–	2012
2022 Q3	$206K	Hold	3,460	–	–	﹤0.01%	1450
2022 Q2	$100K	Buy	+3,460	New	+$100K	﹤0.01%	1445

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Amundi's RXDX Position: Q2 2023 in Review

Amundi sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 65,989 shares — an estimated $7.17M sold.

Amundi first reported a position in RXDX in Q2 2022 and held it in 3 quarters. The position peaked at $7.17M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Amundi reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Amundi sold 65,989 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $7.17M.
Amundi first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Amundi's Prometheus Biosciences, Inc. Common Stock position peaked at $7.17M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.